Patents by Inventor Naoyuki Fukuchi
Naoyuki Fukuchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9440980Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the ? subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the ? subunit of a trimeric GTP-binding protein, as the active ingredient, etc.Type: GrantFiled: April 25, 2014Date of Patent: September 13, 2016Assignee: EA PHARMA CO., LTD.Inventors: Naoyuki Fukuchi, Satoru Okamoto, Wataru Miyanaga, Sen Takeshita, Masaru Takayanagi, Yumiko Fukuda, Takao Ikenoue, Naoyuki Yamada, Naoko Arashida
-
Publication number: 20140309135Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the ? subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the ? subunit of a trimeric GTP-binding protein, as the active ingredient, etc.Type: ApplicationFiled: April 25, 2014Publication date: October 16, 2014Applicant: AJINOMOTO CO., INC.Inventors: Naoyuki FUKUCHI, Satoru Okamoto, Wataru Miyanaga, Sen Takeshita, Masaru Takayanagi, Yumiko Fukuda, Takao Ikenoue, Naoyuki Yamada, Naoko Arashida
-
Patent number: 8772281Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the ? subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the ? subunit of a trimeric GTP-binding protein, as the active ingredient, etc.Type: GrantFiled: December 10, 2012Date of Patent: July 8, 2014Assignee: Ajinomoto Co., Inc.Inventors: Naoyuki Fukuchi, Satoru Okamoto, Wataru Miyanaga, Sen Takeshita, Masaru Takayanagi, Yumiko Fukuda, Takao Ikenoue, Naoyuki Yamada, Naoko Arashida
-
Publication number: 20130041000Abstract: Azole compounds represented by formula I: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic acid (LPA), and are useful as for the prophylaxis or treatment of diseases in which inhibition of the physiological activity of LPA is useful for the prophylaxis or treatment thereof, such as diseases involving the LPA receptor.Type: ApplicationFiled: August 14, 2012Publication date: February 14, 2013Applicant: AJINOMOTO CO., INC.Inventors: Takashi YAMAMOTO, Akira Chiba, Koichi Fujita, Yuka Kataba, Koji Ohsumi, Sayaka Asari, Naoyuki Fukuchi, Misato Noguchi, Itsuya Tanabe, Chiori Ijichi, Naoko Oomuta, Yuko Iida, Satoshi Iwayama
-
Patent number: 8357680Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the ? subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the ? subunit of a trimeric GTP-binding protein, as the active ingredient, etc.Type: GrantFiled: October 7, 2009Date of Patent: January 22, 2013Assignee: Ajinomoto Co., Inc.Inventors: Naoyuki Fukuchi, Satoru Okamoto, Wataru Miyanaga, Sen Takeshita, Masaru Takayanagi, Yumiko Fukuda, Takao Ikenoue, Naoyuki Yamada, Naoko Arashida
-
Publication number: 20130017548Abstract: The present invention relates to a novel method for screening for a therapeutic or prophylactic agent for an inflammatory disease. More particularly, the present invention relates to a method for screening for a therapeutic or prophylactic agent for an inflammatory disease by selecting a substance having an inhibitory activity specific to PIKfyve by using the presence or absence of the inhibitory activity as an indicator.Type: ApplicationFiled: June 27, 2012Publication date: January 17, 2013Applicant: AJINOMOTO, INC.Inventors: Sen Takeshita, Takashi Yamamoto, Ayatoshi Andou, Tomohisa Okutsu, Agung Eviryanti, Naoyuki Fukuchi, Shunsuke Kageyama
-
Patent number: 8318449Abstract: It is intended to provide an assay method whereby the activity of a lipid-modifying enzyme can be conveniently measured over a wide range and a drug capable of controlling a lipid-modifying enzyme with the use of this assay method. The above problem can be solved by, for example, a method of measuring the activity of a lipid-modifying enzyme which comprises the steps of (I) preparing a lipid micelle containing a biotinylated lipid and a substrate for the lipid-modifying enzyme; (II) bringing the lipid micelle prepared in the above step (I) into contact with the lipid-modifying enzyme; and (III) evaluating the activity of the lipid-modifying enzyme by applying an evaluation method using the proximity effect to the product obtained in the above step (II).Type: GrantFiled: November 16, 2009Date of Patent: November 27, 2012Assignee: Ajinomoto Co., Inc.Inventor: Naoyuki Fukuchi
-
Patent number: 7994353Abstract: The present invention provides PPAR (peroxisome proliferator-activated receptor) activity regulators, which can be widely used for improving insulin resistance and preventing/treating various diseases such as diabetes, metabolic syndromes, hyperlipemia, high-blood pressure, vascular disorders, inflammation, hepatitis, fatty liver, liver fibrosis, NASH (non-alcoholic steatohepatitis) and obesity.Type: GrantFiled: March 5, 2009Date of Patent: August 9, 2011Assignee: Ajinomoto Co., Inc.Inventors: Akiko Oonuki, Toshihiko Yoshimura, Katsumi Maezono, Yayoi Kawato, Hideyuki Tanaka, Naoyuki Fukuchi, Nozomu Ishida
-
Patent number: 7879863Abstract: The present invention provides a novel compound having a kininogenase-inhibitory action and its pharmaceutical use. The compounds are represented by the formulas (A), (B), (C), (E) and (H): wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 29, 2006Date of Patent: February 1, 2011Assignee: Ajinomoto Co., Inc.Inventors: Munetaka Tokumasu, Masayuki Sugiki, Haruko Hirashima, Hideki Matsumoto, Toshihiko Yoshimura, Yasuko Nogi, Mitsuo Takahashi, Manabu Kitazawa, Akiko Oonuki, Naoyuki Fukuchi, Yoichiro Shima
-
Patent number: 7745443Abstract: The present invention relates to compounds of the formula I, in which R1, R2, A, B, D, E, n, m or o have the meanings indicated below. The compounds of the formula I are valuable pharmacologically active compounds. They are reversible inhibitors of the interaction between the plasma protein von Willebrand factor (vWF) and the blood platelet receptor glycoprotein Ib-IX-V complex (GPIb). They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of atherothrombotic diseases.Type: GrantFiled: April 2, 2007Date of Patent: June 29, 2010Assignees: Sanofi-Aventis Deutschland GmbH, Ajinomoto Co., Inc.Inventors: Otmar Klingler, Melitta Just, Kuniya Sakurai, Naoyuki Fukuchi
-
Patent number: 7732637Abstract: The present invention provides an acylamide compound of the following formula (1), prodrugs thereof, or pharmaceutically acceptable salts thereof; and an adiponectin inducer or secretagogue, therapeutic agent of metabolic syndromes, therapeutic agent of hypoadiponectinemia, therapeutic agent of hyperlipemia, preventive/therapeutic agent of diabetes, improving agent of impaired glucose tolerance, improving agent of insulin resistance, enhancing agent of insulin sensitivity, therapeutic agent of hypertension, preventive/therapeutic agent of vascular disorders, an anti-inflammatory agent, therapeutic agent of hepatic inflammation, therapeutic agent of fatty liver, therapeutic agent of hepatic fibrosis, therapeutic agent of liver cirrhosis, preventive/therapeutic agent of non-alcoholic/nonviral steatohepatitis (NASH) or non-alcoholic/nonviral fatty liver disease (NAFLD), or therapeutic agent of obesity, each of which has the above compounds as an active ingredient.Type: GrantFiled: August 7, 2007Date of Patent: June 8, 2010Assignee: Ajinomoto Co., Inc.Inventors: Katsumi Maezono, Toshihiko Yoshimura, Nozomu Ishida, Naoyuki Fukuchi, Toshihiro Hatanaka, Osamu Ikehara, Yayoi Kawato, Hideyuki Tanaka
-
Publication number: 20100136578Abstract: It is intended to provide an assay method whereby the activity of a lipid-modifying enzyme can be conveniently measured over a wide range and a drug capable of controlling a lipid-modifying enzyme with the use of this assay method. The above problem can be solved by, for example, a method of measuring the activity of a lipid-modifying enzyme which comprises the steps of (I) preparing a lipid micelle containing a biotinylated lipid and a substrate for the lipid-modifying enzyme; (II) bringing the lipid micelle prepared in the above step (I) into contact with the lipid-modifying enzyme; and (III) evaluating the activity of the lipid-modifying enzyme by applying an evaluation method using the proximity effect to the product obtained in the above step (II).Type: ApplicationFiled: November 16, 2009Publication date: June 3, 2010Applicant: AJINOMOTO CO., INCInventor: Naoyuki FUKUCHI
-
Patent number: 7728158Abstract: The object of the present invention is to provide PPAR (peroxisome proliferator-activated receptor) activity regulators, which can be widely used for improving insulin resistance and preventing/treating various diseases such as diabetes, metabolic syndromes, hyperlipemia, high-blood pressure, vascular disorders, inflammation, hepatitis, fatty liver, liver fibrosis, NASH (non-alcoholic steatohepatitis) and obesity. The present invention provides PPAR activity regulators which comprise an acylamide compound having the specific structure, prodrugs thereof, or pharmaceutically acceptable salts thereof.Type: GrantFiled: May 25, 2007Date of Patent: June 1, 2010Assignee: Ajinomoto Co., Inc.Inventors: Akiko Oonuki, Toshihiko Yoshimura, Katsumi Maezono, Yayoi Kawato, Hideyuki Tanaka, Naoyuki Fukuchi, Nozomu Ishida
-
Publication number: 20100120172Abstract: A method for conveniently detecting binding between the von Willebrand factor and glycoprotein Ib and a means to be used therein. The von Willebrand factor fixed in a reactor immobilized in a reaction vessel in the presence of bottrocetin is bound to a chimeric protein constructed by fusing the carboxyl terminal of a partial protein containing the von Willebrand factor-binding site of glycoprotein Ib with the amino terminal of the Fc region of an immunoglobulin molecule. Then the Fc region of the above immunoglobulin molecule is detected to thereby detect the binding between the von Willebrand factor and the glycoprotein Ib or inhibition of this binding.Type: ApplicationFiled: August 27, 2009Publication date: May 13, 2010Applicant: AJINOMOTO CO., INC.Inventors: Naoyuki Fukuchi, Fumie Futaki, Morikazu Kito, Seiichi Sato, Takayuki Kajiura, Yukitsugu Ono, Koichi Ishii, Akiko Tanaka, Junko Shinozaki, Yasuko Jojima
-
Publication number: 20100093055Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the ? subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the ? subunit of a trimeric GTP-binding protein, as the active ingredient, etc.Type: ApplicationFiled: October 7, 2009Publication date: April 15, 2010Applicant: AJINOMOTO CO., INC.Inventors: Naoyuki Fukuchi, Satoru Okamoto, Wataru Miyanaga, Sen Takeshita, Masaru Takayanagi, Yumiko Fukuda, Takao Ikenoue, Naoyuki Yamada, Naoko Arashida
-
Patent number: 7683077Abstract: The present invention provides a piperidine derivative represented by the following formula or analogs thereto, which are used for agents for treating or preventing various diseases related to 5-HT7.Type: GrantFiled: May 19, 2004Date of Patent: March 23, 2010Assignee: Ajinomoto Co., Inc.Inventors: Shingo Makino, Naoyuki Fukuchi, Sayaka Asari, Masaki Hashimoto, Tetsuo Yano, Youji Yamada, Munetaka Tokumasu, Masataka Shoji, Itsuya Tanabe, Shinichi Fujita, Hideki Matsumoto
-
Publication number: 20100063151Abstract: The present invention provides acylamide compounds, prodrugs thereof, or pharmaceutically acceptable salts thereof; and an adiponectin inducer or secretagogue, and therapeutic methods by administering the same.Type: ApplicationFiled: November 18, 2009Publication date: March 11, 2010Applicant: Ajinomoto Co., Inc.Inventors: Katsumi MAEZONO, Toshihiko YOSHIMURA, Nozomu ISHIDA, Naoyuki FUKUCHI, Toshihiro HATANAKA, Osamu IKEHARA, Yayoi KAWATO, Hideyuki TANAKA
-
Publication number: 20090270455Abstract: The present invention relates to a therapeutic agent for irritable bowel syndrome of diarrhea type, ulcerative colitis, visceral pain or abdominal pain, which contains a compound of the following formula and which has 5-HT7 receptor antagonistic effect or an analogue thereof; and this therapeutic agent has an excellent therapeutic effect and a high safety:Type: ApplicationFiled: July 8, 2009Publication date: October 29, 2009Applicant: AJINOMOTO CO., INC.Inventors: Munetaka Tokumasu, Masaki Hashimoto, Tetsuo Yano, Hideki Matsumoto, Shinichi Fujita, Tetsuya Seki, Sayaka Asari, Naoyuki Fukuchi, Kazuyoshi Takahashi, Masataka Shoji
-
Patent number: 7608695Abstract: A method for conveniently detecting binding between the von Willebrand factor and glycoprotein Ib and a means to be used therein. The von Willebrand factor fixed in a reactor immobilized in a reaction vessel in the presence of bottrocetin is bound to a chimeric protein constructed by fusing the carboxyl terminal of a partial protein containing the von Willebrand factor-binding site of glycoprotein Ib with the amino terminal of the Fc region of an immunoglobulin molecule. Then the Fc region of the above immunoglobulin molecule is detected to thereby detect the binding between the von Willebrand factor and the glycoprotein Ib or inhibition of this binding.Type: GrantFiled: April 16, 2004Date of Patent: October 27, 2009Assignee: Ajinomoto Co., Inc.Inventors: Naoyuki Fukuchi, Fumie Futaki, Morikazu Kito, Seiichi Sato, Takayuki Kajiura, Yukitsugu Ono, Koichi Ishii, Akiko Tanaka, Junko Shinozaki, Yasuko Jojima
-
Publication number: 20090259061Abstract: The object of the present invention is to provide PPAR (peroxisome proliferator-activated receptor) activity regulators, which can be widely used for improving insulin resistance and preventing/treating various diseases such as diabetes, metabolic syndromes, hyperlipemia, high-blood pressure, vascular disorders, inflammation, hepatitis, fatty liver, liver fibrosis, NASH (non-alcoholic steatohepatitis) and obesity. The present invention provides PPAR activity regulators which comprise an acylamide compound having the specific structure, prodrugs thereof, or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: March 5, 2009Publication date: October 15, 2009Applicant: AJINOMOTO, CO., INC.Inventors: Akiko OONUKI, Toshihiko YOSHIMURA, Katsumi MAEZONO, Yayoi KAWATO, Hideyuki TANAKA, Naoyuki FUKUCHI, Nozomu ISHIDA